Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.